Victoria Homer

Medicine & Life Sciences

1. Pseudotumor Cerebri 100%
2. timolumab 73%
3. Clinical Trials 49%
4. Headache 40%
5. Sclerosing Cholangitis 37%
6. Rectal Neoplasms 30%
7. Organ Preservation 28%
8. Papilledema 26%
9. Adaptive Clinical Trials 25%
10. Transanal Endoscopic Microsurgery 25%
11. Cohort Studies 23%
12. Radiotherapy 22%
13. Prospective Studies 21%
14. GATA2 Deficiency 20%
15. Actinic Keratosis 19%
16. Medulloblastoma 17%
17. Dehydroepiandrosterone 17%
18. Feasibility Studies 17%
19. Medical Oncology 17%
20. Blood Vessels 17%
21. Maximum Tolerated Dose 17%
22. Watchful Waiting 16%
23. Randomized Controlled Trials 16%
24. Maternal Health 16%
25. Polycystic Ovary Syndrome 16%
26. Acetic Acid 15%
27. Wounds and Injuries 15%
28. Disease Progression 15%
29. Optical Coherence Tomography 15%
30. Burns 15%
31. Rectum 14%
32. Drug Development 13%
33. Transplant Recipients 13%
34. Registries 13%
35. Cerebrospinal Fluid 12%
36. Guidelines 12%
37. Monoclonal Antibodies 12%
38. Squamous Cell Carcinoma 12%
39. Alkaline Phosphatase 12%
40. Proteins 12%
41. Pregnant Women 11%
42. Quality of Life 11%
43. Vaccination 11%
44. Therapeutics 11%
45. Nerve Fibers 10%
46. Ganglia 9%
47. Visual Fields 9%
48. Cross-Sectional Studies 9%
49. Transplants 9%
50. Phenotype 8%